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Abstract 
Background: NK cells contribute to tumour surveillance, inhibition of growth and dissemination by cytotoxicity, 
secretion of cytokines and interaction with immune cells. Their precise role in human breast cancer is unclear and the 
effect of therapy poorly studied. The purpose of our study was to characterise NK cells in women with large (≥3 cm) 
and locally advanced (T3–4, N1–2, M0) breast cancers (LLABCs) undergoing neoadjuvant chemotherapy (NAC) and 
surgery, and to ascertain their possible contribution to a pathological complete response (pCR).
Methods: Women with LLABCs (n = 25) and healthy female donors [HFDs (n = 10)] were studied. Pathological 
responses in the breast were assessed using established criteria. Blood samples were collected pre and post NAC and 
surgery. Flow cytometry and labelled monoclonal antibodies established absolute numbers (AbNs) and percentages 
(%) of NK cells, and expressing granzyme B/perforin and NKG2D. In vitro NK cytotoxicity was assessed and NK cells and 
cytokines (IL‑2, INF‑γ, TGF‑β) documented in tumours using immunohistochemical techniques. Data was analysed by 
SPSS.
Results: Women with LLABCs had significantly reduced AbNs (160.00 ± 40.00 cells/µl) but not % of NK cells, com‑
pared with HFDs (NK: 266.78 ± 55.00 cells/µl; p = 0.020). NAC enhanced the AbN (p = 0.001) and % (p = 0.006) 
of NK cells in patients with good pathological responses. Granzyme B+/perforin+ cells were significantly reduced 
(43.41 ± 4.00%), compared with HFDs (60.26 ± 7.00%; p = 0.003). NAC increased the % in good (p = 0.006) and poor 
(p = 0.005) pathological responders. Pretreatment NK cytotoxicity was significantly reduced in good (37.80 ± 8.05%) 
and poor (22.80 ± 7.97%) responders (p = 0.001) but remained unchanged following NAC. NK‑NKG2D+ cells were 
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unaltered and unaffected by NAC; NKG2D expression was increased in patients with a pCR (p = 0.001). Surgery fol‑
lowing NAC was not beneficial, except in those with a pCR. Tumour‑infiltrating NK cells were infrequent but increased 
peritumourally (p = 0.005) showing a significant correlation (p = 0.004) between CD56+ cells and grade of response. 
Tumour cytokines had no effect.
Conclusion: Women with LLABCs have inhibited blood innate immunity, variably reversed by NAC (especially with 
tumour pCRs), which returned to pretreatment levels following surgery. These and in situ tumour findings suggest a 
role for NK cells in NAC‑induced breast pCR.
Keywords: Breast cancer, Neoadjuvant chemotherapy, NK cells
Background
Natural killer (NK) cells have been shown in various 
tumour models in mice to play an important role in tumour 
immune surveillance, in the prevention of progressive 
tumour growth and in the defence against metastatic dis-
semination [1–3]. Although most established tumours in 
animal models have very low levels of NK cells, adoptively 
transferred ex vivo activated NK cells readily infiltrate 
tumours and induce tumour cell death [4]. However, in situ 
production of interleukin-2 (IL-2) and IL-15 is necessary to 
continually reactivate these infiltrating NK cells to prevent 
NK cell exhaustion and inhibition by the tumour milieu 
suppressor cellular and humoral factors [5, 6].
In man, evidence is emerging that NK cells also play an 
important anticancer role, albeit this is less well defined 
[7]. Epidemiological studies have shown that chronic low 
levels of NK cell activity is associated with an increased 
incidence of cancer and NK cell cytotoxicity to be signifi-
cantly lower in individuals with a high incidence of familial 
cancer [8, 9]. Reduced levels of circulating NK cell activ-
ity in uterine and colorectal cancers were shown to pre-
dispose to metastatic dissemination [10, 11]. Most human 
tumours have very low levels of infiltration by NK cells. 
However, where there was more prominent infiltration of 
cancers (colorectal, lung, renal, gastric, vulval) by NK cells, 
this was shown to be associated with an improved progno-
sis and reduction in tumour recurrence [12–17].
In humans, blood NK cells are bone-marrow-derived 
granular lymphocytes and are a subset of the cytotoxic 
innate lymphoid pool, exerting their cytotoxicity with-
out prior sensitisation, recognising and eliminating tar-
get cells (stressed, damaged or malignant) by sensing 
loss of self-major histocompatibility complex (MHC) 
class I molecules on these cells, the process being mod-
ulated by various activating and inhibitory molecules 
[18–20]. A number of NK cell subsets have been recently 
characterised, the most prevalent (and cytotoxic) being 
the CD16+CD56dim subset (85–90%), followed by the 
CD16−CD56bright subset (5–10%) (which is noncytotoxic 
and produces cytokines); the remaining three subsets 
make up approximately 5% of the residual NK cell popu-
lation [21, 22]. An important mechanism of the NK cell 
antitumour effect, apart from tumour cell lysis, occurs 
via the secretion of interferon-gamma (INF-γ), activation 
of T lymphocytes and the selective generation of immu-
nogenic dendritic cells (DCs) [23, 24].
There is conflicting data in the literature about NK cell 
cytotoxicity and levels in the blood, and a dearth of infor-
mation about the tumour microenvironment in women 
with breast cancer. Women with early and operable 
breast cancer have been documented as showing a varia-
ble level in blood of NK cell cytotoxicity, but comparable 
with that in healthy donors. However, other investigators 
have reported low levels of NK cell cytotoxicity in women 
with breast cancer. Garner et  al. showed a progressive 
reduction in NK cell cytotoxicity with advanced breast 
cancer [25]. Konjevic et  al. also demonstrated a signifi-
cantly depressed NK cell activity in patients with breast 
cancer with progression of disease [26]. A recent study 
has documented a decreased expression of INF-γ and 
pSTAT contributing to the dysregulation in NK cells iso-
lated from the blood of women with breast cancer [27]. 
We documented previously low numbers of NK cells and 
NK cell cytotoxicity in mononuclear cells isolated from 
tumours in women undergoing surgical removal of the 
breast [28]. However, this aspect is very poorly docu-
mented in the literature.
Evidence is accumulating that some cytotoxic com-
pounds promote specific anticancer immune responses 
which contribute to the therapeutic effects of chemo-
therapy. Both adaptive and innate immune mechanisms 
appear to contribute to this anticancer response [29, 30]. 
Chemotherapy, by damaging or stressing cells, can lead to 
the release of various “danger” signals which activate DCs 
and NK cells and induce the release of proinflammatory 
cytokines. Treatment with taxanes and doxorubicin have 
been shown to release IL-2, IL-6, IL-8 and IFN-γ [31, 32]. 
Cancer cells are known to have suboptimal expression 
of MHC class I molecules rendering them susceptible to 
damage and death by activated NK cells [33].
We have carried out a study evaluating the effect of dif-
ferent NAC combinations on the pathological response, 
in particular pathological complete response (pCR), of 
the tumour in the breast. This has afforded an excellent 
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opportunity to carefully study the effect of NAC on the 
phenotypic profile and cytotoxic activity of blood NK 
(CD16+CD56dim) cells in women with LLABCs undergo-
ing NAC and surgery. We also investigated the tumour 
cell milieu by documenting immunohistochemically the 
infiltration by CD56+ cells and the presence of in situ 
cytokines (IL-2, INF-γ and transforming growth factor-
beta [TGF-β]) with recognised stimulatory and inhibitory 
effects in NK cells. Our study has documented signifi-
cant cellular and functional reductions in NK cells in the 
blood of women with LLABCs, differential augmenta-
tions with NAC (influenced by the pathological response, 
in particular pCR elicited in the breast cancer by NAC) 
but with a return to pretreatment baseline levels follow-
ing subsequent surgery. We also documented the signifi-
cant association and correlation of tumour-infiltrating 
NK cells and pCRs elicited by NAC.
Patients and methods
Patients
Women with LLABCs (≥3  cm, T3–4, N1–2, M0), were 
enrolled in a trial of NAC to evaluate the effect of the 
addition of capecitabine (Cap) to doxetaxel (T) preceded 
by doxorubicin and cyclophosphamide (AC). All patients 
received either 4 courses of AC followed by 4 courses 
of T ± Cap or 2 courses of AC followed by 6 courses of 
T ± Cap. All patients underwent surgery (wide local exci-
sion or mastectomy, and axillary surgery) 4  weeks after 
the last course of NAC. Pathological responses in the 
breast were assessed in the excised surgical specimens 
after NAC. Pre NAC assessment was done on core biop-
sies, obtained prior to commencement of NAC. An estab-
lished and previously published grading criteria was used 
to define histopathological responses (grades 5–1) [34].
The study was given approval by the Leicestershire, 
Northamptonshire and Rutland Research Ethics Com-
mittee 1: Reference Number 07/H0406/260; Favourable 
Opinion 24/01/2008. All patients enrolled in the study 
gave informed consent to participate in and to pub-
lish the results of the study. The study Registration is 
ISRCTN00407556.
A cohort of 25 women enrolled into the trial under-
went various blood immunological investigations. Tis-
sue samples (pre and post NAC) from 16 patients of 
this cohort were examined immunohistochemically for 
different immune parameters. The relevant findings are 
reported in this manuscript.
Preparation of BMCs
Blood samples were collected from patients before com-
mencing NAC and 3–4  weeks following completion of 
NAC and before surgery, by which time NK cell recovery 
has occurred [35]. Samples were also collected 2–3 weeks 
following surgery, when NK cell numbers and function 
are known to have returned to pre-surgical levels [36]. 
Blood samples from ten age- and sex-matched healthy 
female donors (HFDs) were used to establish normal NK 
cell profiles. Blood mononuclear cells (BMCs) were col-
lected on Ficoll-Hypaque, washed and made up in RPMI 
with 10% foetal calf serum (FCS) (Sigma, UK) and antibi-
otics (TCM), and stored at −80°C until further analysis. 
BMCs were used to establish the % of NK cells. Whole 
blood assays were carried out on venepuncture blood 
samples to document absolute numbers (AbNs) of NK 
cells.
Phenotypic characterisation of absolute numbers (AbNs) 
of NK cells in blood
NK (CD3−CD56dim) cells were characterised using 5 μl 
fluorescein isothiocyanate (FITC) anti-human CD3 and 
5  μl phycoerythrin (PE) antihuman CD56, (Beckman 
Coulter, UK). On adding the labelled monoclonal anti-
bodies (MAbs) a gentle vortex was applied for 5  s and 
the FACS tubes were left in the dark for 15 min at room 
temperature (RT). 500  μl of optilyse C solution (Beck-
man Coulter, UK) was added to induce complete lysis of 
red blood cells, vortexed and left for another 15  min at 
RT in the dark. 500 μl of phosphate buffered saline (PBS) 
was added to the FACS tubes to stop the lysis reaction 
between the optilyse C and the whole blood. The whole 
blood mixture was vortexed at RT. 100 μl of flow count-
fluorsphere beads (Beckman Coulter, UK) was added 
prior to analysis on the flow cytometer (Beckman Coul-
ter, FC500). Total events acquired were 150,000.
Phenotypic characterisation of percentage (%) of NK cells 
and natural‑killer group 2, member D (NKG2D) expression 
in blood
Flow cytometric analysis (Beckman Coulter, FC500) 
was performed with a panel of labelled MAbs (Beck-
man Coulter, UK). NK (CD3−CD16+CD56dim) cells were 
characterised by harvesting 1 × 106 cells/100 μl of BMCS 
and stained for cell surface markers for 30 min with 5 μl 
FITC antihuman CD3, 5  μl PE antihuman CD56, and 
5  μl phycoerythrin-texas red (ECD) antihuman CD16 
MAbs. Expression of NKG2D was determined using allo-
phycocyanin (APC) antihuman NKG2D MAbs. The cells 
were then washed with RPMI and 2% FCS. The BMCs 
were resuspended in 400  μl of 0.5% paraformaldehyde 
fixative solution for flow cytometric analysis. Total events 
acquired were 150,000.
Phenotypic characterisation of percentage (%) of NK cells 
and granzyme B and perforin expression in blood
The BMCs were washed with RPMI and 2% FCS; 2% for-
maldehyde was used for fixation of BMCs for 10 min at 
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RT. The BMCs were then washed once in PBS contain-
ing 2% FCS, and twice in PBS/0.5% Tween with 0.05% 
azide and 3% FCS. 2.5  μl of a 1:20 optimised dilution 
of FITC antihuman perforin and 1 μl of 1:20 optimised 
dilution Alexa Fluor 647 mouse antihuman granzyme B 
(ebiosciences, UK), 5 μl phycoerythrin-cyanine 7 (PCY7) 
antihuman CD3, 5 μl PE antihuman CD56 and 5 μl ECD 
antihuman CD16 MAbs (Beckman Coulter, UK) were 
added to the corresponding tubes and incubated for 2 h 
at 4°C (shaking gently every 20  min). The BMC pellet 
was then washed twice in PBS/0.5% Tween, 0.05% azide 
and 3% FCS. The BMCs were resuspended in 400 μl of 
0.5% paraformaldehyde fixative solution for flow cyto-
metric analysis, using the Beckman Coulter FC500. Lym-
phocyte regions were selected and gated onto the NK 
(CD3−CD16+CD56dim) cells. Further gating of the NK 
lymphocytes was applied onto the granzyme B+ and per-
forin+ double-labelled cells. Dead cells were excluded 
from analysis according to their forward and side scatter 
characteristics. Total events acquired were 150,000 cells.
In vitro natural cytotoxicity assays
The ability of NK cells to induce apoptosis or necro-
sis of K562 target cells was assessed in vitro. K562 cells 
which had been subcultured for 24  h previously were 
counted and resuspended at a density of 1 × 106 cells/ml 
in RPMI/10% FCS. Preliminary studies had shown that 
a tumour:effector ratio of 1:10 gave the optimal level of 
cytotoxicity. K562 cells were incubated for 20  min with 
5 μl of Vibrant Dil solution (Invitrogen, UK) in serum-
free medium at 37°C for 30 min and washed twice (cen-
trifuged at 250g for 10  min in PBS). Cells were seeded 
into FACS tubes at a K562:PBMC ratio (T:E ratio) of 1:10 
(AbNs of K562 were 1 × 104; PBMCS 1 × 105) and incu-
bated at 37°C (5% CO2) for 4 h. Following this, the cells 
were washed in PBS once and stained with Annexin-V 
FITC 10 μl and Topro 10 μl (Pharmingen, UK) for 20 min. 
Cells were then washed twice in PBS and resuspended in 
300 μl PBS. Cells were analysed by flow cytometry (Beck-
man Coulter, FC500) on the same day within 4 h of the 
experiment. Once stained with Annexin-V FITC and 
Topro 10, target cell damage and lysis was determined by 
flow cytometric gating on vibrant Dil-positive K562 cells. 
The percentage of Annexin-V high (apoptotic) and Topro 
10 high (necrotic) cells, within this population was deter-
mined and the combined % described as the % of dead 
cells. Total events acquired were 150,000.
Immunohistochemical staining and quantification
Immunohistochemical assessments of CD56+ cells, 
IL-2, INF-γ and TGF-β, were performed in 4-µm tissue 
sections from core biopsies of breast cancers. Briefly, 
paraffin-embedded tissue sections were dewaxed and 
rehydrated using xylene and graded alcohol. Citrate 
buffer, pH 6.0, at 98°C was added for 20  min for anti-
gen retrieval. After serial blocking, the sections were 
incubated with the primary MAb against CD56 (Dako, 
M7304, clone 123 C3), 1:50 dilution for 30  min at RT; 
MAb against IL-2 (Abcam, ab92381, clone EPR2780), 
1:500 dilutionl for 30  min at RT; MAbs against TGF-
β1 (Abcam, ab64715, clone 2Ar2), 12  µg/ml overnight 
at 4°C; polyclonal antibody against INF-γ (Abcam, 
ab9657), 4 µg/ml for 30 min at RT. The Novolink™ poly-
mer detection system, Leica RE7280-K with polymeric 
horseradish peroxidase (HRP)-linker antibody conju-
gates and diaminobenzidine (DAB) chromogen, was 
used for enzyme-substrate labelling. Finally, the sections 
were counterstained with haematoxylin, dehydrated and 
mounted in DPX mounting medium. Positive and nega-
tive staining controls were carried out with tonsil sec-
tions. Negative staining controls were demonstrated by 
omitting the primary antibody.
To evaluate the extent of CD56+ lymphocytic infiltra-
tion in the breast cancers, the total number of brown 
membrane-stained cells, regardless of the intensity, were 
counted in 5 high power fields (HPFs) (400×). CD56+ 
cells in contact with tumour cells or within the tumour 
cells nests were defined as “intratumoural” whereas 
CD56+ cells in the interstitial stroma surrounding 
tumour nests were defined as “peritumoural”.
To evaluate the presence of IL-2, INF-γ and TGF-β 
in the breast cancers the semi-quantitative H scoring 
system was used. The H score was calculated by mul-
tiplying the % of positive cells by a factor representing 
the intensity of immune-reactivity (1 for weak, 2 for 
moderate and 3 for strong), giving a maximum score of 
300 (3+). A score of <50 was considered negative and a 
score of 50–100 was considered weakly positive (1+). A 
score of 101–200 was regarded as moderately positive 
(2+) and a score of 201–300 as strongly positive (3+). 
Negative and 1+ were considered as low expression 
whereas 2+ and 3+ were considered as high expres-
sion. For TGF-β the sections were scored as negative or 
positive.
To evaluate tumour-infiltrating lymphocytes (TILs) on 
haematoxylin and eosin (H&E)-stained sections, intra-
tumoural lymphocytes (Itu-Ly) were reported as the % 
of the tumour epithelial nests that contained infiltrating 
lymphocytes. Stromal lymphocytes (Str-Ly) were defined 
as the % of tumour stromal area that contained a lympho-
cytic infiltrate without direct contact with tumour cells. 
Scores of >60% were considered to be high levels of infil-
tration, while ≤60% were considered to be low levels of 
infiltration for both Itu-Ly and Str-Ly. Cases were defined 
as high TILs when Itu-Ly and/or Str-Ly were >60% and as 
low TILs if Itu-Ly and Str-Ly were ≤60% [37].
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Evaluation and grading of pathological response  
in the breast
Patients were allocated to responder groups accordingly: 
Group I (grade 5, pathological complete response [pCR], 
no residual invasive tumour cells in specimens); Group 
II (grade 4, very good pathological response, >90% loss 
of tumour cells); Group III (grade 3, partial pathologi-
cal response, between 30 and 90% reduction in tumour 
cells); Group IV (grade 2, very poor response, <30% 
tumour cell loss) and grade 1 no pathological response, 
no change in overall cellularity) [34].
Statistical analysis
Flow cytometric data was analysed using WEASEL ver-
sion 3.0. All dependent variables were checked by the 
Shapiro–Wilk Test of Normality to establish the normal 
distribution or otherwise of the data obtained. SPSS (ver-
sion 19.0) was used in analysis of data to calculate inde-
pendent sample t tests for observing statistical differences. 
The Mann–Whitney U test and Kruskal–Wallis test were 
used to analyse infiltrating NK cells in pre NAC and post 
NAC tumour samples. Pearson Chi square test was used 
to analyse in situ cytokines. The Wilcoxon signed rank 
test was used to compare cell numbers in related samples 
before and after NAC. Spearman’s correlation coefficient 
(rho) was used to correlate graded pathological responses 
with infiltrating NK cells. A probability value of <0.05 
(p < 0.05) was considered statistically significant.
Results
Reduction in the absolute numbers (AbNs) (but not %) 
of NK cells in the blood of women with LLABCs
There was no difference in the % of NK (CD3− 
CD16+CD56dim) cells in the circulation of women with 
LLABCs, compared with HFDs (Table 1). There was, how-
ever, a substantial and significant reduction in the AbNs 
of NK (CD3−CD56dim) cells (160.0 ± 40.00 cells/µl) in the 
circulation of women with LLABCs, compared with HFDs 
(266.78 ± 55.00 cells/µl) (p = 0.020) (Table 1).
NAC increased the % and AbNs of NK cells in the blood 
of women with LLABCs
The % of NK (CD3−CD16+CD56dim) cells in the circula-
tion of patients following eight cycles of NAC revealed 
a heterogeneous profile, depending on the type of 
pathological response elicited in the breast cancers follow-
ing NAC (Table 2). Patients whose tumours demonstrated 
a partial or poor pathological response (Groups III and 
IV), showed no alteration in the % of circulating NK cells, 
compared with pretreatment baseline levels. However, 
those patients whose tumours elicited a pCR (Group I) or 
very good (Group II) pathological response demonstrated 
a significant increase in the % of NK cells (14.77 ± 2.00%) 
in the circulation, compared with pretreatment baseline 
levels (6.50  ±  2.50%) (p  =  0.006). In Group I patients, 
whose tumours demonstrated a pCR (14.52 ± 3.00%), this 
increased level was significantly higher than that docu-
mented in HFDs (6.00 ± 1.50%) (p = 0.001) (Table 2).
Due to the small number of blood samples (n  =  7) 
available for NK (CD3−D56dim) cell AbN analysis, the 
data from all the Groups were pooled, and not tabu-
lated. NAC significantly increased the AbN of NK cells 
(314.29 ± 10.00 cells/μl), when compared with pretreat-
ment levels (182.83  ±  21.50  cells/µl) (p  =  0.001). The 
levels were now comparable with those documented in 
HFDs (266.78 ± 55.00 cells/µl) (p = 0.441).
Surgical resection following NAC resulted in the return 
of the blood NK cells (%, AbNs) to pretreatment levels
Following surgery, the % of NK (CD3−CD16+CD56dim) 
cells in the circulation of patients returned back to pre-
treatment levels, irrespective of a good or a poor patho-
logical response elicited in the tumour following NAC 
(Table  2). However, women who had a pCR still had a 
significantly increased % of NK cells (11.60 ± 3.00%), fol-
lowing surgery, when compared with HFDs (6.00 ± 1.50%) 
(p = 0.007).
The AbN of NK (CD3−CD56dim) cells following surgery 
(188.71 ± 25.50 cells/µl) also returned back to pretreat-
ment levels (182.83 ± 21.50 cells/µl).
Reduced cytotoxicity (granzyme B/perforin expression, 
in vitro K562 cell death) of NK cells in the blood of women 
with LLABCs
The % of double-staining granzyme B+/perforin+ NK 
(CD3−CD16+CD56dim) cells was significantly reduced 
(43.41 ± 4.00%) in the circulation of women with LLABCs, 
compared with HFDs (60.26 ± 7.00%) (p = 0.003) (Table 3).
In vitro cytotoxicity (apoptosis/necrosis) of K562 cells 
was also significantly reduced in women with LLABCs 
Table 1 Presence of natural killer (NK) cells in the circulation (%, AbN) in women with LLABCs and HFDs
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), HFDs healthy female donors.
* Values significantly reduced.
Cell phenotypes In the circulation of women  
with LLABCs (n = 25)
In the circulation  
of HFDs (n = 10)
P value
NK (CD3−CD16+CD56dim) (%) 8.50 ± 4.00 6.00 ± 1.75 0.805
NK (CD3−CD56dim) (AbN:cells/µl) 160.0 ± 40.00 266.78 ± 55.00 0.020*
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compared with HFDs (Figure  1). There was, however, a 
differential effect depending on the subsequent patho-
logical response elicited in the breast cancers with NAC. 
[Groups I and II: 37.8  ±  8.50% (p  =  0.001); Groups III 
and IV: 22.8 ± 7.97 (p = 0.001); HFDs: 69.70 ± 10.00%]. 
Patients with the poorest pathological response to NAC 
had the most pronounced reduction of pretreatment 
cytotoxicity (p = 0.017) (Figure 1).
NAC enhanced granzyme B/perforin expression  
but not in vitro cytotoxicity of NK cells in the blood 
of women with LLABCs
Following NAC (8 cycles) there was a significant 
increase in the % of double-staining granzyme B+/
perforin+ NK (CD3−CD16+CD56dim) cells, com-
pared with pretreatment levels (Groups I and II: 
40.60  ±  6.50%; Groups III and IV: 28.26  ±  5.00%) 
in both the good (Groups I and II: 63.03  ±  10.0%) 
(p = 0.006) and poor (Groups III and IV: 60.10 ± 16.0%) 
(p =  0.005) pathological responders to NAC. Thus, in 
all patient groups following NAC the % of granzyme 
B+/perforin+ NK cells was enhanced and comparable 
with the % levels documented in HFDs (60.26 ± 2.50%) 
(Table 4).
Following eight cycles of NAC, in vitro cytotoxicity 
(apoptosis/necrosis) of K562 cells was unaltered in either 
the good (Groups I and II) or poor (Groups III and IV) 
pathological responders to NAC (Figure 2).
Table 2 NK (CD3−CD16+CD56dim) cells in the blood of women with LLABCs (n = 16) undergoing NAC and subsequent sur-
gery
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherpy, HFDs healthy female donors.
** VALUES significantly increased.
Baseline (B) levels in LLABCs versus (v) completion of chemotherapy (CC) levels in different responders
Study group comparisons NK (%)
Good pathological responders B 6.50 ± 2.50
[Groups I and II] CC 14.77 ± 2.00
(n = 9) CC v B P = 0.006**
Poor pathological responders B 7.23 ± 1.50
[Groups III and IV] CC 7.01 ± 2.00
(n = 7) CC v B P = 0.115
Complete pathological responders PCR 14.52 ± 3.00
[PCR] (n = 6) HFDs 6.00 ± 1.75
Healthy female donors (HFDs) (n = 10) PCR v HFDs P = 0.001**
Baseline (B) levels in LLABCs versus (v) post surgical resection (SR) levels in different responders
Study group comparisons NK (%)
Good pathological responders B 6.50 ± 1.50
[Groups I and II] SR 9.31 ± 2.10
(n = 9) SR v B P = 0.147
Poor pathological responders B 7.23 ± 1.50
[Groups III and IV] SR 5.00 ± 2.20
(n = 7) SR v B P = 0.128
Complete pathological responders PCR 11.60 ± 3.00
[PCR] (n = 6) HFDs 6.00 ± 1.75
Healthy female donors (HFDs) (n = 10) PCR v HFDs P = 0.007**
Table 3 NK (CD3−CD16+CD56dim) cells expressing granzyme B/perforin (cytotoxic activity) and NKG2D (activation) in the 
circulation of women with LLABCs and HFDS
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), HFDs healthy female donors.
* Values significantly reduced.
Cell phenotypes and  
functional status
% in the circulation of  
women with LLABCs (n = 25)
% In the circulation  
of HFDs (n = 10)
P value
NK granzyme B+/perforin+ 43.41 ± 4.00 60.26 ± 7.00 0.003*
NK‑NKG2D+ 8.32 ± 3.50 4.00 ± 1.50 0.078
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Surgical resection following NAC resulted in the 
return of the blood NK granzyme B+/perforin+ cells 
to pretreatment baseline levels and had no effect on NK 
cell cytotoxicity
Surgery had no significant beneficial effect on the % of 
granzyme B+/perforin+ NK (CD3−CD16+CD56dim) cells, 
with values returning to reduced pretreatment baseline 
levels. Even patients whose tumours showed a pCR had 
significantly suppressed levels of granzyme B+/perforin+ 
NK cells (47.50  ±  8.00), when compared with HFDs 
(60.26 ± 2.50) (p = 0.032).
Following surgery, the reduced levels of in vitro NK cell 
cytotoxicity (apoptosis/necrosis) was unaltered in either 
the good (Groups I and II) or poor (Groups III and IV) 
pathological responders to NAC (Figure 2).
Activation status (NKG2D+) of NK cells in the blood 
of women with LLABCs and the effect of NAC and surgery
There was no significant alteration in expression of 
NKG2D on NK (CD3−CD16+CD56dim) cells in the cir-
culation of women with LLABCs, when compared with 
HFDs, albeit there was a tendency for it to be elevated 
(p = 0.078) (Table 3). Following NAC (8 courses), there 
was no significant change in phenotypic profile. However, 
patients whose tumours showed a pCR had a significantly 
increased % of NK-NKG2D+ cells, compared with HFDs 
(p =  0.001). This profile remained unchanged following 
surgery. In patients with a pCR the % of NK-NKG2D+ 
cells continued to be significantly increased, compared 
with HFDs (p = 0.001) (Table 5).
Representative examples of FACS analysis (pre and post 
NAC, and post surgery) from patients whose breast cancers 
had a pCR following NAC and HFDs
Figure  3 shows examples from representative patients 
whose breast cancers had a pCR with NAC and from HFDs. 
Dot plot diagrams (A: AbN NK cells; B: % NK cells; C: % 
granzyme B+/perforin+ NK cells) of FACS analysis prior to 
and post NAC, and following surgery are shown. The find-
ings mirror the data presented in Tables 2 and 4. Histogram 
(D: NK-NKG2D+ cells) of FACS analysis prior to and post 
NAC, and following surgery is shown (dark histogram is 
control). The findings mirror data presented in Table 5.
Clinical and pathological characteristics of patients 
with LLABCs investigated (blood n = 25, tumour n = 16)
Clinical and pathological characteristics of the patients 
studied are shown in Table  6. A cohort of 25 women 
enrolled into the trial underwent various blood immuno-
logical investigations. Tumour samples from 16 patients 
from this cohort were examined immunohistochemically 
for specific immune parameters. There were no obvious 
characteristics to account for the level and type of pre 
NAC CD56+ tumour infiltrates.
Immunohistological assessment of cells infiltrating LLABCs 
(n = 16): pre NAC (TILs, and CD56+ cells) and post NAC 
(CD56+ cells)
Figure 4 is a photograph of TILs infiltrating LLABCs; (A) 
low level of lymphocytic infiltration and (B) high level of 
lymphocytic infiltration, of tumour nests and/or stromal 
areas. There was no association with any specific clin-
icopathological characteristic and degree of infiltration 
(Table 6).
Table  7 shows the distribution of tumour-infiltrat-
ing CD56+ cells in the tumour microenvironment of 
breast cancers. This is well illustrated in the photograph 
depicted in Figure  5 showing intratumoural (Itu) and 
peritumoural (Str) infiltration. The distribution within 
tumour nests was not predictive of the subsequent path-
ological responses elicited following NAC. However, 
peritumoural stromal infiltration was significantly asso-
ciated with the type of subsequent pathological response 

























Figure 1 Blood NK cell cytotoxicity (apoptosis and necrosis of K562 
cells—see “Patients and methods” for further details) elicited by 
BMCs from women with LLABCs, prior to NAC, and HFDs. Differential 
cytotoxicity documented depending on the subsequent pathologi‑
cal response elicited in the breast cancers after NAC. [Groups I and 
II (good responders): 37.8 ± 8.50%; Groups III and IV (poor respond‑
ers): 22.8 ± 7.97%; HFDs 69.7 ± 10.0%]. There is a significant and 
graduated reduction of NK cell cytotoxicity in the different groups 
of responders to NAC (Groups I and II versus Groups III and IV 
[p = 0.017]). The most substantial reduction, compared with HFDs, 
was seen in poor responders (Groups III and IV) (p = 0.001). Sponta‑
neous cytotoxicity in the assays was ≤4%. SPSS (version 19.0) used 
for data analysis and calculation of independent sample t tests for 
statistical significance.
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Table 4 NK (CD3−CD16+CD56dim) granzyme B+/perforin+ cells in the blood of women with LLABCs (n = 16) undergoing 
NAC and subsequent surgery
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherapy, HFDs healthy female donors.
* Values significantly reduced, ** values significantly increased.
Baseline (B) levels in LLABCs versus (v) completion of chemotherapy (CC) levels in different responders
Study group comparisons NK granzyme B+/perforin (%)
Good pathological responders B 40.60 ± 2.50
[Groups I and II] CC 63.03 ± 10.00
(n = 9) CC v B P = 0.006**
Poor pathological responders B 28.26 ± 5.00
[Groups III and IV] CC 60.10 ± 16.00
(n = 7) CC v B P = 0.005**
Complete pathological responders PCR 66.28 ± 6.00
[PCR] (n = 6) HFDs 60.26 ± 2.50
Healthy female donors (HFDs) (n = 10) PCR v HFDs P = 0.105
Baseline (B) levels in LLABCs versus (v) post surgical resection (SR) levels in different responders
Study group comparisons NK granzyme B+/perforin (%)
Good pathological responders B 40.60 ± 6.50
[Groups I and II] SR 44.17 ± 10.0
(n = 9) SR v B P = 0.156
Poor pathological responders B 28.26 ± 5.00
[Groups III and IV] SR 49.46 ± 10.0
(n = 7) SR v B P = 0.158
Complete pathological responders PCR 47.50 ± 8.00
[PCR] (n = 6) HFDs 60.26 ± 2.50















































Figure 2 Blood NK cell cytotoxicity (apoptosis and necrosis of K562 cells—see “Patients and methods” for further details) elicited by BMCs for 
Groups I and II and Groups III and IV women with LLABCs undergoing NAC. There was no significant difference observed between baseline levels 
(prior to NAC) (Groups I and II: 38.3 ± 8.40%; Groups III and IV: 22.4 ± 7.6%), following eight cycles of chemotherapy (Groups I and II: 45.2 ± 4.40%; 
Groups III and IV: 24.4 ± 1.50%) and after surgery (Groups I and II: 35 ± 3.00%; Groups III and IV: 22.4 ± 2.90%). Spontaneous activity in the assays 
was ≤4%. SPSS (version 19.0) used for data analysis and calculation of independent sample t tests for statistical significance.
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a pCR (present versus absent; p = 0.005) following NAC 
(Table 7).
There were no significant differences between the 
immunohistochemical assessment of CD56+ cells in the 
operative specimens (post NAC) and the pre NAC core 
biopsies, albeit there were fewer cells in the post NAC 
specimens (Table 7).
Significant correlation between tumour‑infiltrating 
CD56+ cells in pre NAC tumours and subsequent grade 
of pathological response
There was a significant correlation between the level 
of pre NAC peritumoural infiltrating CD56+ cells and 
the subsequent grade of response (p  =  0.001) to NAC 
(Table  8). There was also a tendency for a correlation 
between intratumoural CD56+ cells and the subsequent 
grade of response, but this did not reach statistical sig-
nificance (p = 0.077) (Table 8).
Cytokines (IL‑2, INF‑γ, TGF‑β) expressed in situ in breast 
cancers (n = 16) pre NAC core biopsies and post NAC 
excision samples
Figures 6, 7 and 8 illustrate the presence and distribution 
of IL-2, INF-y and TGF-β, respectively. These cytokines 
are shown to be expressed on both tumour cells and stro-
mal lymphocytes. There was no significant difference in 
the in situ expression of IL-2, INF-γ and TGF-β in the 
good versus poor pathological responders to NAC. Also, 
there was no significant difference in patients whose 
tumours had a pCR versus those that did not (Table 9).   
Following NAC, there was similarly no significant dif-
ference in in situ expression of IL-2, INF-γ, and TGF-β, 
albeit there was a tendency for high expression of TGF-β 
in tumours that failed to achieve a pCR (p  =  0.062) 
(Table 9). Analysis of in situ cytokine expression between 
pre and post NAC breast specimens did not demonstrate 
any significant difference (related samples McNemar 
Test)—data not shown.
Discussion
Our study has defined more precisely, not only the sta-
tus of the mature, cytotoxic circulating NK cell subset 
(CD3−CD16+CD56dim) in women with LLABCs, but also 
the significant and differential effect of NAC and followed 
by surgery on this status. Our results further confirm 
the significant and substantial inhibition of aspects of 
innate immunity in women with LLABCs (in the absence 
of overt metastatic disease) and the selective beneficial 
Table 5 NK (CD3−CD16+CD56dim) NKG2D+ cells in the blood of women with LLABCs (n  =  16) undergoing NAC and 
subsequent surgery
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherapy, HFDs healthy female donors.
* Values significantly reduced, ** values significantly increased.
Baseline (B) levels in LLABCs versus (v) completion of chemotherapy (CC) levels in different responders
Study group comparisons NK–NKG2D (%)
Good pathological responders B 6.94 ± 3.00
[Groups I and II] CC 13.53 ± 4.50
(n = 9) CC v B P = 0.241
Poor pathological responders B 4.27 ± 2.00
[Groups III and IV] CC 9.35 ± 4.00
(n = 7) CC v B P = 0.789
Complete pathological responders PCR 13.53 ± 3.50
[PCR] (n = 6) HFDs 4.00 ± 1.50
Healthy female donors (HFDs) (n = 10) PCR v HFDs P = 0.001**
Baseline (B) levels in LLABCs versus (v) post surgical resection (SR) levels in different responders
Study group comparisons NK–NKG2D %
Good pathological responders B 6.94 ± 3.00
[Groups I and II] SR 10.08 ± 5.00
(n = 9) SR v B P = 0.614
Poor pathological responders B 4.27 ± 2.00
[Groups III and IV] SR 3.76 ± 10.0
(n = 7) SR v B P = 0.168
Complete pathological responders PCR 15.34 ± 4.00
[PCR] (n = 6) HFDs 4.00 ± 1.50
Healthy female donors (HFDs) (n = 10) PCR v HFDs P = 0.001**
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effect of NAC on these immune parameters. We also pro-
vide an insight as to the possible role of innate immune 
mechanisms, in particular, NK cells in the tumour micro-
environment, in inducing a pCR in the breast of women 
undergoing NAC and thereby contributing to a good 
long-term clinical outcome.
Our investigation documented no change in the % 
of NK cells but a substantial and significant reduc-
tion of AbNs of NK cells in the blood of women with 
LLABCs. This is at variance with the increased % of 
NK cells previously documented by Murta et  al. who 
described an increased % and AbNs of NK cells in the 
Figure 3 a Is an example (dot plot diagram) from a representative patient from Group 1 (pCR) and a HFD of FACS analysis of AbNs of NK 
(CD3−CD56dim) cells in the blood at baseline (prior to NAC), post NAC and post surgery. b Is an example (dot plot diagram) from a representative 
patient from Group 1 (pCR) and a HFD of FACS analysis of % NK (CD3−CD16+CD56dim) cells in the blood at baseline (prior to NAC), post NAC and 
post surgery. c Is an example (dot plot analysis) from a representative patient from Group 1 (pCR) and a HFD of FACS analysis of % of granzyme B+/
perforin+ NK (CD3−CD16+CD56dim) cells in the blood at baseline (prior to NAC), post NAC and post surgery. d Is an example (histogram) from a 
representative patient from Group 1 (pCR) and a HFD of FACS analysis (dark histogram is control) of % of NK‑NKG2D+ (CD3−CD16+CD56dim) cells at 
baseline (prior to NAC), post NAC and post surgery.
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blood of such patients [38]. Recently, Muraro et al. also 
demonstrated an increased % of NK cells, but only in 
women with HER2/neu −ve tumours (commonest 
type); patients with HER2/neu +ve tumours showed no 
alteration in % of NK cells in blood [39]. In the results 
reported here, 18 of the 25 patients studied had HER2/
neu −ve cancers. There is a paucity of data in the pub-
lished literature about AbNs of NK cells in the circula-
tion in women with breast cancer. It is not clear as to 
why there is this difference in the % of NK cells between 
our findings and the results of the above two studies. A 
likely explanation is the documentation of different NK 
cell subsets. The more mature and cytotoxic subset of 
NK cells (CD16+CD56dim) was studied in our investiga-
tion. The results obtained in our study (reduced AbNs, 
inhibited in vitro cytotoxicity) are in keeping with the 
recently published data, showing an increased propor-
tion of more immature and noncytotoxic NK cells in the 
blood of women with more advanced breast cancer [14, 
40, 41].
Table 6 Clinical and pathological characteristics of patients with LLABCs investigated for blood CD56+ parameters 
(n = 25) and tumour-infiltrating CD56+ parameters (n = 16)b
LLABCs large (≥ 3 cm) and locally advanced breast cancers (T3–4 N1–2 M0): all had 8 courses of NAC, 22 tumours were ductal, 2 lobular and 1 metaplastic, TILs tumour-
infiltrating lymphocytes, NAC neoadjuvant chemotherapy, NA not applicable.
a Part of the same cohort of patients: all had 8 courses of NAC, 15 tumours were ductal and 1 metaplastic.
b Oestrogen receptor status (Allred scoring system used to assess oestrogen receptor status).
c Human epidermal growth factor receptor 2 status (FISH: in situ hybridisation).
d Doxorubicin, cyclophosphamide, taxotere and Xeloda® (capecitabine), respectively.
e Total cell count per 5 HPFs.
f Mann–Whitney U test.
g Kruskal–Wallis test.




Pre NAC intratumoural 
median (range)e




 <50 9 5 1 (0–6) 0.510 1 (0–1) 0.090
 ≥50 16 11 3 (0–17) 2 (0–17)
Menopausal status
 Pre 10 7 2 (0–7) 0.918 1 (0–17) 0.536
 Post 15 9 1 (0–17) 2 (0–11)
Tumour size (clinical)
 <40 mm 14 9 1 (0–17) 0.470 1 (0–17) 0.536
 ≥40 mm 11 7 5 (0–7) 2 (0–5)
Nodal metastasis
 Negative 15 9 3 (0–17) 0.351 2 (0–17) 0.071
 Positive 9 7 1 (0–6) 1 (0–3)
Tumour grade
 1 (low) 2 2 4 (1–7) 0.152g 2.5 (0–5) 0.082g
 2 (moderate) 14 7 1 (0–6) 1 (0–2)
 3 (high) 9 7 5 (0–17) 3 (0–17)
ERb status
 Negative 5 4 4 (1–17) 0.262 3 (2–11) 0.058
 Positive 20 12 1 (0–7) 1 (0–17)
HER2c status
 Negative 18 13 3 (0–17) 0.189 1 (0–17) 1.000
 Positive 7 3 1 (0–1) 2 (0–3)
TILs
 Low NA 9 1 (0–7) 0.091 1 (0–5) 0.091
 High NA 7 5 (1–17) 3 (0–17)
NAC regimen
 ACTXd 11 5 3 (0–7) 0.661 2 (0–17) 0.441
 ACT 14 11 1 (0–17) 1 (0–11)
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NAC was found to significantly increase both the % 
and AbNs of circulating NK cells. There was a differ-
ential beneficial effect depending on the pathological 
response in the cancer in the breast after eight courses 
of NAC. Patients whose tumours showed a pCR (patho-
logical complete response with no residual invasive dis-
ease) or a very good pathological response (very small 
residual focus of invasive disease) demonstrated the most 
pronounced enhancement of NK cell levels (%) in blood; 
these were higher than levels documented in HFDs. There 
were corresponding significantly augmented levels of 
blood AbNs of NK cells, but due to the small sample size 
available it was not possible to assess circulating NK cell 
levels according to pathological responses elicited in the 
breast cancer with NAC. The effect of NAC on circulat-
ing levels of innate lymphoid cells is poorly documented. 
Murta et  al. demonstrated that FEC (5-fluorouracil, epi-
rubicin, and cyclophosphamide) NAC increased both the 
% and AbNs of NK cells, which is in agreement with our 
findings [38]. An earlier study did not demonstrate any 
change with NAC [42]. Different NAC regimens may have 
different effects on NK cell subsets and their functional 
Figure 4 TILs in the sections of LLABCs, using H&E staining, at ×200 magnification. a Low level of lymphocytic infiltration, b high level of lympho‑
cytic infiltration. Low level of TILs defined as ≤60% of tumour nests and/or stromal areas infiltrated by lymphocytes. High level of TILs defined as 
>60% of tumour nests and/or stromal areas infiltrated by lymphocytes.
Table 7 Analyses of tumour-infiltrating CD56+ cells in LLABCs pre and post NAC
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherapy.
* Statistically significant.
a Total cell count per 5 HPFs (core biopsies of breast cancers).
b Mann–Whitney U test.
c Wilcoxon signed rank test.




P valueb  
(GPR versus  
PPR, PCR  
versus  
non PCR)




P valueb  
(GPR versus  
PPR, PCR  
versus  
non PCR)









response (GPR, n = 9)
5 (0–17) 0.091 2 (0–17) 0.042* 1 (0–3) 0.121
Poor pathological 
response (PPR, n = 7)
1 (0–7) 0 (0–5) 1 (0–3) 0.655
Pathological complete 
response (PCR, n = 6)
4 (1–17) 0.181 3 (2–17) 0.005* 2 (0–3) 0.144
Non pathological com‑
plete response (non 
PCR, n = 10)
1 (0–7) 0.5 (0–5) 1 (0–3) 0.680
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activity. Taxanes, in particular, used in our NAC combi-
nations but not in the studies mentioned above, induce 
the release of IL-2 nd INF-y, both of which are impor-
tant for NK cell survival and function [29, 31]. This 
offers an explanation for the increase in % and AbNs of 
the CD3−CD16+CD56dim NK cell subset following NAC, 
although the cytotoxic activity remained inhibited.
Surgery (mastectomy or wide local excision and axil-
lary lymph node dissection) following the completion of 
eight cycles of NAC did not further improve the blood 
levels of NK cells. In fact, the % and AbN of NK cells in 
the circulation returned back to the pretreatment levels. 
This occurred irrespective of whether the pathological 
response elicited in the breast cancer prior to surgery 
was good or bad. However, patients whose tumours 
showed a pCR (likely absence of metastatic disease) fol-
lowing NAC still showed a prominent % of NK cells in 
the blood (greater than HFDs) following surgical resec-
tion. Information on the effect of breast cancer surgery 
on circulating levels of NK cells is sparse, one previous 
study documenting no change in the % of blood NK cells 
following surgery [42]. Thus, the effect of surgery, alone 
or following NAC, on the circulating NK cells is poorly 
documented. The return to baseline levels after sur-
gery indicates a relatively short-lived effect of NAC. The 
persistently elevated levels of NK cells in the presence 
of a pCR suggests the absence or minimal presence of 
residual occult metastatic disease in view of the benefi-
cial clinical outcome with tumour pCRs [43, 44]. Breast 
cancer, in particular LLABC, should be regarded as a 
systemic disease with locoregional manifestations [45]. 
Those patients with a return of NK cells to pretreatment 
levels following removal of the persistent locoregional 
cancer after NAC are likely to harbour occult metastases.
Figure 5 CD56+ NK cells in the sections of LLABCs, using IHC staining, at ×400 magnification. Briefly, heat‑mediated antigen retrieval was per‑
formed using citrate buffer, pH 6 (20 min). The sections were then incubated with MAbs to CD56 (Dako, M7304) at a 1:50 dilution for 30 min at RT. 
Polymeric HRP‑linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The sections were 
counterstained with haematoxylin. a Low level of CD56+ NK cell infiltration, b high level of CD56+ NK cell infiltration. The total number of brown 
membrane‑stained cells, regardless of intensity, in contact with tumour cells or within tumour cell nests (Itu: intratumoural) and in the interstitial 
stroma (Str: peritumoural) in 5 HPFs were counted.
Table 8 Correlation between tumour-infiltrating CD56+ NK cells and grade of pathological response [Spearman’s correla-
tion coefficient (rho)] in patients with LLABCs pre NAC (n = 16)
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherapy.
* Statistically significant.
a Pathological responses were graded from grade 1 (no pathological response) to grade 5 (complete pathological response)
Groups Pre NAC CD56+ NK cells
Intratumoural infiltrating Peritumoural infiltrating
Grade of pathological responsea Correlation coefficient 0.454 0.683
P value (2‑tailed) 0.077 0.004*
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Blood NK cell cytotoxicity has been studied exten-
sively in patients with a variety of solid tumours. How-
ever, there is conflicting data in the literature about NK 
cell cytotoxicity in women with breast cancer. NK cell 
cytotoxicity has been reported to be comparable with 
healthy controls in some studies [46, 47]. Other inves-
tigators, on the other hand, have reported low levels of 
NK cell cytotoxicity in women with breast cancer, in par-
ticular in women with advanced cancer or progression of 
disease [25, 26, 48–50]. With increasing tumour burden 
and more advanced disease a more immature and less 
cytotoxic subset has been documented in the circula-
tion, and this offers an explanation for the reduced lev-
els of cytotoxicity documented in our study of patients 
Figure 6 IL‑2 expression in the sections of LLABCs, using IHC staining, at ×200 magnification. Briefly, heat‑mediated antigen retrieval was per‑
formed using citrate buffer, pH 6 (20 min). The sections were then incubated with MAbs to IL‑2 (Abcam, ab92381) at a 1:500 dilution for 30 min at 
RT. Polymeric HRP‑linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The sections were 
counterstained with haematoxylin. a Low level of IL‑2 expression, b high level of IL‑2 expression. The H score [% of positive cells × intensity of stain‑
ing (1–3)] was used to assess the level of expression; low was ≤100 and high was >100. Scoring performed on whole tissue section (>10 HPFs).  
Itu intratumoural, Str peritumoural.
Figure 7 INF‑γ expression in the sections of LLABCs, using IHC staining, at ×200 magnification. Briefly, heat‑mediated antigen retrieval was 
performed using citrate buffer, pH 6 (20 min). The sections were then incubated with polyclonal Abs to INF‑γ (Abcam, ab9657) at a concentration 
of 4 µg/ml for 30 min at RT. Polymeric HRP‑linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the 
staining. The sections were counterstained with haematoxylin. a Low level of INF‑γ expression, b high level of INF‑γ expression. The H score [% 
of positive cells × intensity of staining (1–3)] was used to assess the level of expression; low was ≤100 and high was >100. Scoring performed on 
whole tissue section (>10 HPFs). Itu intratumoural, Str peritumoural.
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with LLABCs [14, 40, 41]. Our investigation showed a 
substantial and significant reduction of blood NK cell 
cytotoxicity in women with LLABCs, this being most 
pronounced in women whose tumours responded poorly 
to NAC. We studied the more mature and cytotoxic NK 
(CD3−CD16+CD56dim) cell subset, which was substan-
tially reduced (AbNs) in our patients and offers corrobo-
rating evidence for the low level of NK cell cytotoxicity 
documented in women with LLABCs. Also, there was 
a significant reduction in the % of granzyme B/perforin 
expressing NK cells in this group of patients, compared 
with HFDs. The reduced level of NK cell granzyme B/
perforin expression was more significantly inhibited in 
those patients whose tumours had a partial or poor path-
ological response to NAC. This latter group of patients 
demonstrated the lowest level of NK cytotoxicity (in 
vitro target cell lysis). Although NAC (eight cycles) sig-
nificantly enhanced the % of NK cell granzyme B/per-
forin expressing cells in all patient groups (comparable to 
HFDs), it did not augment in vitro NK cell cytotoxicity. 
In women with advanced breast cancer. Konjevic et  al. 
have documented in NK cells a decreased expression of 
INF-y and pSTAT1, which is probably contributing to the 
reduced cytotoxicity documented [27, 51].
The effect of chemotherapy on NK cell cytotoxic activ-
ity has been investigated in only a small number of stud-
ies in women with breast cancer, and the findings are not 
well defined [52]. Adjuvant chemotherapy (cyclophos-
phamide, methotrexate, and 5-fluorouracil) has been 
shown to significantly decrease blood NK cell cytotox-
icity [53]. Moreover, Mackay et  al., found that persis-
tent low levels of NK cell cytotoxicity following adjuvant 
chemotherapy was associated with a poor outcome [47]. 
In advanced breast cancer, taxanes have been shown to 
increase NK cell cytotoxic activity [31, 54]. Enhancement 
of NK cell cytotoxicity was associated with an improved 
clinical response [48]. The taxane docetaxel was an 
important component of the NAC used in our study. 
The effect of NAC is poorly documented, with NAC 
reported as having an inhibitory effect on NK cell cyto-
toxic activity, when studied in a small number of patients 
[42]. Our investigation demonstrated a differential effect 
of NAC, depending on the efficacy of chemotherapy in 
inducing tumour cell death in the breast. NK cell cyto-
toxicity was most reduced in poor pathological breast 
cancer responders to NAC. However, there was no ben-
eficial enhancement of NK cell cytotoxicity, compared 
with pretreatment baseline levels following NAC. On the 
other hand, NAC did significantly increase the % of gran-
zyme B+/perforin+ NK cells, irrespective of the tumour 
response to NAC. Interestingly, patients with a pCR had 
granzyme B/perforin levels comparable with HFDs.
NK cells induce target cell death through the release of 
perforin and granzyme B, resulting in damage to intracel-
lular proteins, structures and cell membranes leading to 
rapid and effective apoptosis and cell death [55–57]. The 
interactivity of NK cells with target cells (via activatory/
inhibitory receptor/ligand signalling) leads to release of 
granzyme B/perforin into the synaptic cleft, with mem-
brane pore formation and passive transmembrane gran-
zyme B diffusion [57]. Impaired binding of perforin on 
the surface of tumour cells is a recognised cause of target 
cell resistance against cytotoxic effector cells [57]. This 
may be an important factor in our failure to enhance in 
Figure 8 TGF‑β expression in the sections of LLABCs, using IHC staining, at ×200 magnification. Briefly, heat‑mediated antigen retrieval was per‑
formed using citrate buffer, pH 6 (20 min). The sections were then incubated with MAbs to TGF‑β (Abcam, ab64715) at a concentration of 12 µg/ml 
for overnight at 4°C. Polymeric HRP‑linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. 
The sections were counterstained with haematoxylin. a Low level of TGF‑β expression, b high level of TGF‑β expression. The H score [% of positive 
cells × intensity of staining (1–3)] was used to assess the level of expression; sections were scored as negative or positive. Scoring performed on 
whole tissue section (>10 HPFs). Itu intratumoural, Str peritumoural.
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vitro NK cell cytotoxicity with NAC, as we did signifi-
cantly increase the blood levels of the mature, cytotoxic 
NK (CD3−CD16+CD56dim) cell subset by NAC [55, 57]. 
Granzyme B, part of a family of serine proteases, proteo-
lytically activates a range of cell death caspases directly or 
indirectly as well as disrupting mitochondria, resulting in 
degradation of a large number of intracellular proteins. A 
biologically efficient and active granzyme B/perforin pro-
cess is crucial as an anticancer defence mechanism [55]. 
However, it may also enhance T regulatory cell (Tregs) 
immune suppression and release of apoptosis-inducing 
caspases suppressing release of important proinflam-
matory cytokines and granzymes [58, 59]. This may be 
another mechanism for suppressing cytotoxic activity by 
NK cells in the patients studied [55, 56, 60, 61].
The effect of surgery on NK cell cytotoxicity is poorly 
studied. A recent study has reported that following 
mastectomy the level of blood NK cell cytotoxicity was 
increased, compared with pretreatment levels. How-
ever, the post surgical levels of NK cell cytotoxicity was 
Table 9 Analyses of IL-2, IFN-γ and TGF-β expression in LLABCs pre NAC and post NAC
LLABCs large (≥3 cm) and locally advanced breast cancers (T3–4 N1–2 M0), NAC neoadjuvant chemotherapy.
a TGF-β was scored as negative and positive.






































2 5 6 1
Pathological com‑
plete response 
(PCR, n = 6)
2 4 0.019 0.889 3 3 1.571 0.210
Non pathological 
complete response 
(Non PCR, n = 10)










2 5 2 5
Pathological com‑
plete response 
(PCR, n = 6)
0 6 1.371 0.242 2 4 0.71 0.790
Non pathological 
complete response 
(Non PCR, n = 10)










3 4 1 6
Pathological com‑
plete response 
(PCR, n = 6)
4 2 0.423 0.515 4 2 3.484 0.062
Non pathological 
complete response 
(Non PCR, n = 10)
5 5 2 8
Page 17 of 21Verma et al. J Transl Med  (2015) 13:180 
still significantly lower, when compared with healthy 
donors [62]. An earlier study documented a significant 
inhibition of NK cell cytotoxicity following surgery in 
women with breast cancer [42]. In our study, surgery fol-
lowing pretreatment with NAC did not alter the persis-
tently reduced levels of blood NK cell cytotoxic activity, 
as assessed by in vitro target cell death. The enhanced 
expression of granzyme B/perforin induced by NAC, 
however, fell to pretreatment levels following surgery. 
This is in contrast to the findings of Beitsch et  al., who 
showed a significant inhibition of NK cell cytotoxicity 
following surgery in a small cohort of women with LLA-
BCs who, like our patients, had undergone pretreatment 
with NAC [42]. The underlying mechanism for this dif-
ferent response is unclear, but a small cohort of patients 
and different chemotherapeutic drug combinations in the 
latter study are probably important considerations [42].
An important factor in optimal natural cytotoxicity is 
the summation of the interaction of the inhibitory and 
activatory signalling receptors on the cytotoxic cells with 
tumour/target cell-expressed ligands [51, 63–66].
The activating receptor NKG2D on NK cells (inves-
tigated in our study) and its ligand MHC chain-related 
molecule (MIC), expressed on a variety of human can-
cers, are believed to play an important role in both 
tumour initiation and progression [67–69]. In mice 
various cytokines (e.g., IL-2, IL-12, IL-15) enhance the 
expression and signalling by NKG2D, whilst IFN-γ and 
TGF-β downregulate its expression and activity [70, 71]. 
NKG2D ligands (MIC A and B, UL-16 binding proteins) 
are usually expressed in various human tumours, includ-
ing breast cancer [72, 73]. The significance of NKG2D 
expression on NK cells in humans with cancer, however, 
is controversial.
In our study expression of NKG2D on blood NK 
cells was higher than the levels documented on HFDs. 
Although this did not reach statistical significant 
(p  =  0.078). It was, however, significantly enhanced in 
those patients whose breast cancer had a pCR with NAC 
and this persisted even after surgery. Concurrent inves-
tigation of Tregs and myeloid-derived suppressor cells 
(MDSCs), and in vitro production of T helper 1 (Th1) 
and Th2 cytokines in our patients (previously reported) 
demonstrated a significantly enhanced numbers of sup-
pressor cells (only partially abolished by NAC) and 
polarisation of Th2 profiles (unaltered by NAC). These 
immune considerations may have contributed to the 
findings obtained [74].
Activity of NK cell subsets are also modulated by 
inhibitory receptors such as killer immunoglobulin-like 
receptors (KIRs), which are dependent on HLA gene 
polymorphisms [75, 76]. They inhibit NK cell function 
via a tyrosine-based inhibitory motif as well as blocking 
cytoskeleton-dependent receptors [77]. These inhibitory 
factors were not investigated in our study and their con-
tribution to persistent NK cell dysfunction requires fur-
ther evaluation.
Soluble NKG2D ligands (sMICs) are effective in down 
regulating NKG2D expression on NK and other effec-
tor cells in patients with cancer leading to Fas-mediated 
caspases activation and cleavage of CD3ζ and NK cell 
dysfunction [78]. In patients with prostate cancer, sMIC 
impaired this ability of NK cells to self renew thus affect-
ing blood NK cell homeostasis and accelerated metastatic 
dissemination [79]. This may be an important factor in 
the persistence of reduced blood NK cell cytotoxicity in 
our patients, in particular where NAC failed to induce a 
pCR in the breast cancer. Konjevic et al. have previously 
shown an inhibitory effect on in vitro NK cell cytotoxic-
ity of serum from patients with advanced breast cancer 
[51]. They showed that decreased NK cell cytotoxicity 
was due to low levels of pSTAT1 and INF-γ but did not 
investigate the role of sMICs [51]. In breast cancer MIC 
expression on tumours has been documented to have 
variable effects, enhanced survival in early breast cancer 
and a poor outcome in high grade tumours [73, 80].
Tumours have been shown to inhibit NK cell func-
tion by modulation of expression of activating recep-
tors and cytolytic activity, through release of indolamine 
2, 3-dioxygenase (IDO), TGF-β and prostaglandin E2 
(PGE2) by malignant cells and Tregs [74, 81, 82]. In early 
breast cancer, lack of MHC class I expression on can-
cer cells was associated with a significantly higher risk 
of breast cancer relapse [73]. Women whose tumours 
underwent a pCR (a well established surrogate marker 
of good clinical outcome) with NAC, had a significantly 
increased % of NKG2D expressing cells post NAC as well 
as post surgery. These findings suggest an enhanced acti-
vation of NK cell activity by NAC. The results support the 
significant correlation between CD56+ cells infiltrating 
breast tumours and a subsequent pCR post NAC docu-
mented in our study. Secretion of IDO, PGE2 and lack of 
MHC class I molecules expression and ligand expression 
for NKG2D on tumour cells are key factors contributing 
to T and NK cell immunoevasion [64, 83, 84]. We have 
recently documented the very prominent level of Tregs 
and MDSCs in the blood of women with LLABCs, and 
the significant reduction of these inhibitory cells by NAC, 
especially when the tumour underwent a pCR [74].
The tumour microenvironment is a very complex and 
crucial milieu for tumour cell damage and regression 
of tumour growth, but it is also the environment that 
enhances progressive tumour growth and dissemina-
tion due to cellular and humoral suppressor mecha-
nisms inhibiting the adaptive and innate anticancer 
defences [85]. Natural killer (NK) cells have been shown 
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in various tumour models in mice to play an important 
role in tumour immune surveillance, in the prevention 
of progressive tumour growth and in the defence against 
metastatic dissemination [1–3].
Although most established tumours in animal models 
have very low levels of NK cells, adoptively transferred 
ex vivo activated NK cells readily infiltrate tumours and 
induce tumour cell death [4]. However, in situ produc-
tion of IL-2 and IL-15 is necessary to continually reacti-
vate infiltrating NK cells to prevent NK cell exhaustion 
and inhibition by the tumour milieu suppressor cells 
and humoral factors, such as TGF-β [5, 6]. Most human 
tumours have very low levels of infiltration by NK cells. 
However, where there was more prominent infiltration of 
cancers (colorectal, lung, renal, gastric, vulval) by NK cells, 
this was shown to be associated with an improved prog-
nosis and reduction in tumour recurrence [12, 13, 15–17].
There is a dearth of published evidence regarding 
tumour-infiltrating NK cells in human breast cancer. Our 
study has confirmed the pattern of infiltration shown 
with a range of human solid tumours, namely the very 
low levels of infiltration and the improved outcome with 
increasing levels of NK cell infiltration [12, 13, 15–17]. In 
our study, there was a significant increase of NK cells in 
the peritumoural environment in patients whose breast 
cancers showed a good pathological response, especially 
a pCR following NAC, a well established good prog-
nostic indicator [43, 44]. We did not demonstrate any 
association between in situ tumour levels of IL-2, INF-γ 
or TGF-β and the pathological response elicited in the 
breast by NAC, highlighting the complexity and multi-
factorial interplay between the host defences and cancer 
cells in the tumour milieu.
Our study has documented the significant inhibition 
of specific aspects of natural immunity in blood (NK cell 
subsets, NK cell cytotoxicity) in women with LLABCs. 
This was probably induced by the high level of circulat-
ing Tregs and MDSCs present in these women [74]. Our 
previous study also documented a major polarisation, 
in terms of production of Th1 and Th2 cytokines by the 
blood T lymphocytes. There was a substantial and sig-
nificant inhibition of Th1 and substantial and significant 
augmentation of Th2 cytokine production, which per-
sisted following NAC and subsequent surgery [74]. The 
very substantially reduced production of IL-2 and INF-γ, 
de novo and after NAC, probably contributed to the per-
sistently reduced NK cell numbers and activity following 
treatment in our patients. This persistent dysfunction of 
natural immunity following NAC and subsequent surgery 
may have an important bearing as to the likelihood of 
subsequent tumour recurrence in patients with LLABCs, 
especially where there was failure to achieve a pCR in the 
breast cancers with NAC.
Conclusion
Women with LLABCs have significantly inhibited 
aspects of innate immunity. This innate immune sup-
pression is reversed to a variable degree by NAC. This 
reversal is most pronounced and constant in patients 
whose breast cancer elicited a pCR with NAC. How-
ever, following surgery, the immune parameters 
return to pretreatment levels except in those patients 
whose breast cancers had a pCR, when the % of NK 
CD3−CD16+CD56dim and NK-NKG2D+ cells continue 
to be significantly elevated (comparable to HFDs). Our 
results suggest an important role for these anticancer 
immune mechanisms, especially during NAC. Failure 
to augment these suppressed immune responses with 
NAC may partly explain the suboptimal effect of NAC 
in some patients and the associated increased risk of 
subsequent tumour recurrence in patients with LLA-
BCs whose breast cancers fail to achieve a pCR. Fur-
ther studies to monitor post-treatment immune status 
and association with tumour recurrence are required 
and may suggest novel adjuvant immunotherapeutic 
interventions to improve disease-free survival in such 
patients.
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